Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03133793 · ClinicalTrials.gov registry record · Phase 2
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT03133793 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 216 participants.
The verdict
NCT03133793, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
Interventions
- OTHER Placebo powder
- DRUG CoQ10
- DRUG D-Ribose Oral Powder
- OTHER Placebo pills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2021-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03133793
The ClinicalTrials.gov registry entry for NCT03133793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo powder is the first listed.
NCT03133793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03133793 about?
NCT03133793 is a clinical study titled "CoQ10 and D-ribose in Patients With Diastolic Heart Failure". The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
What is the current status of trial NCT03133793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2018-02-05. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT03133793?
The interventions under investigation include: Placebo powder (OTHER), CoQ10 (DRUG), D-Ribose Oral Powder (DRUG), Placebo pills (OTHER).
Who is sponsoring clinical trial NCT03133793?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.